Citizens Financial Group Inc. RI Has $11.59 Million Stake in Pfizer Inc. $PFE

Key Points

• Citizens Financial Group increased its Pfizer stake by 34.8% in Q4 to 465,598 shares, worth about $11.59 million, as institutional investors now own roughly 68.4% of the stock.
• Pfizer posted several positive developments — a Phase 3 win for ELREXFIO, a patent settlement extending U.S. protection for VYNDAMAX to 2031, and FDA acceptance of a supplemental BLA for PADCEV — strengthening key oncology and tafamidis revenue prospects.
• Management declared a quarterly dividend of $0.43 (annualized $1.72) for a 6.4% yieldHold with an average price target of $28.74 ahead of Q1 results.

Citizens Financial Group Inc. RI grew its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 34.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 465,598 shares of the biopharmaceutical company's stock after purchasing an additional 120,089 shares during the period. Citizens Financial Group Inc. RI's holdings in Pfizer were worth $11,593,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Horizon Financial Services LLC boosted its position in shares of Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 645 shares in the last quarter. YANKCOM Partnership acquired a new stake in shares of Pfizer during the 4th quarter valued at about $28,000. Grey Fox Wealth Advisors LLC acquired a new stake in shares of Pfizer during the 3rd quarter valued at about $29,000. Darwin Wealth Management LLC acquired a new stake in shares of Pfizer during the 2nd quarter valued at about $32,000. Finally, True Wealth Design LLC boosted its position in shares of Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 974 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PFE. Bank of America decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research report on Thursday, April 9th. Zacks Research upgraded shares of Pfizer from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 24th. Morgan Stanley lifted their target price on shares of Pfizer from $27.00 to $28.00 and gave the company an "equal weight" rating in a research report on Friday, April 10th. BMO Capital Markets reiterated an "outperform" rating and set a $30.00 target price on shares of Pfizer in a research report on Monday, March 9th. Finally, HSBC lifted their target price on shares of Pfizer from $29.00 to $32.00 and gave the company a "buy" rating in a research report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $28.74.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late‑stage trial win for ELREXFIO (elranatamab): Pfizer reported Phase 3 MagnetisMM‑5 results showing a statistically significant improvement in progression‑free survival for relapsed/refractory multiple myeloma, strengthening ELREXFIO’s commercial potential in a high‑value oncology indication. Reuters: Pfizer's blood cancer drug meets main goal in late-stage trial
• Positive Sentiment: VYNDAMAX patent settlement extends US protection to 2031: Pfizer reached settlements with multiple generics makers that effectively push off generic entry for its tafamidis franchise, protecting an asset Reuters and industry reports estimate is worth several billion in annual sales. This preserves a key revenue stream. Yahoo Finance: Pfizer reaches settlement to extend VYNDAMAX patent protection
• Positive Sentiment: FDA accepted sBLA for PADCEV (priority review): Pfizer and Astellas announced the US FDA accepted a supplemental Biologics License Application for PADCEV, advancing a potential label expansion that could add to oncology revenues if approved. InsiderMonkey: Pfizer Among Best Medical Stocks Under $30 to Invest In?
• Neutral Sentiment: Q1 earnings preview and estimates: Analysts and services are focused on Pfizer’s May 5 Q1 report; consensus (Zacks) currently forecasts ~$13.8B in sales and $0.74 EPS, so results that deviate from these metrics could move the stock. Zacks: Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings
• Neutral Sentiment: Market positioning and product markets: Reports note Pfizer’s participation in growing OTC markets (e.g., dry‑eye drops) and ongoing analyst coverage that highlights mixed sentiment — positive for pipeline progress but cautious on near‑term growth. Yahoo Finance: $4+ Billion OTC Dry Eye Drops Market Analysis
• Negative Sentiment: Competitive pressure from Alnylam’s Amvuttra: Alnylam’s strong Q1 beat and a near‑200% move for its heart‑disease drug underscore competitive dynamics in certain cardiometabolic portfolios — a reminder that product launches by peers can affect market share and sentiment in overlapping indications. Yahoo Finance: Alnylam surges after its Pfizer‑rivaling blockbuster jumps nearly 200%
• Negative Sentiment: Minor analyst estimate tweaks: Erste Group made a very small FY2027 EPS trim, and some analysts express mixed views — not a large revision but a headwind if further downgrades occur ahead of earnings. (No link)

Pfizer Trading Up 1.8%

Shares of PFE stock opened at $26.75 on Friday. Pfizer Inc. has a 12-month low of $21.97 and a 12-month high of $28.75. The company has a market capitalization of $152.08 billion, a P/E ratio of 19.67 and a beta of 0.43. The firm has a 50-day moving average price of $27.17 and a 200 day moving average price of $26.09. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same period last year, the firm posted $0.63 EPS. The firm's quarterly revenue was down 1.2% on a year-over-year basis. Research analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.4%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer's dividend payout ratio (DPR) is currently 126.47%.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.